U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07591805) titled 'HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC' on May 04.
Brief Summary: This is a prospective, single-center, single-arm phase II study evaluating whether a single postoperative intravesical instillation of disitamab vedotin (RC48) can reduce bladder recurrence after radical nephroureterectomy (RNU) in patients with HER2-positive upper tract urothelial carcinoma (UTUC). Eligible patients will receive one intravesical instillation of RC48 within 96 hours after surgery. The primary objective is to determine the 12-month intravesical recurrence rate. Serial urine samples will be prospectively collected to evaluate urinary methy...